Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin

P. Alberti; E. Rossi; D. R. Cornblath; I. S. J. Merkies; T. J. Postma; B. Frigeni; J. Bruna; R. Velasco; A. A. Argyriou; H. P. Kalofonos; D. Psimaras; D. Ricard; A. Pace; E. Galie; C. Briani; C. Dalla Torre; C. G. Faber; R. I. Lalisang; W. Boogerd; D. Brandsma; S. Koeppen; J. Hense; D. Storey; S. Kerrigan; A. Schenone; S. Fabbri; M. G. Valsecchi; G. Cavaletti

doi:10.1093/annonc/mdt409

Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin

P. Alberti, E. Rossi, D. R. Cornblath, I. S. J. Merkies, T. J. Postma, B. Frigeni, J. Bruna, R. Velasco, A. A. Argyriou, H. P. Kalofonos, D. Psimaras, D. Ricard, A. Pace, E. Galie, C. Briani, C. Dalla Torre, C. G. Faber, R. I. Lalisang, W. Boogerd, D. BrandsmaS. Koeppen, J. Hense, D. Storey, S. Kerrigan, A. Schenone, S. Fabbri, M. G. Valsecchi, G. Cavaletti^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

111 Citations (Web of Science)

Abstract

Background: The different perception and assessment of chemotherapy-induced peripheral neurotoxicity (CIPN) between healthcare providers and patients has not yet been fully addressed, although these two approaches might eventually lead to inconsistent, possibly conflicting interpretation, especially regarding sensory impairment. Patients and methods: A cohort of 281 subjects with stable CIPN was evaluated with the National Cancer Institute-Common Toxicity Criteria (NCI-CTC v. 2.0) sensory scale, the clinical Total Neuropathy Score (TNSc (c)), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) sensory sumscore (mISS) and the European Organization for Research and Treatment of Cancer CIPN specific self-report questionnaire (EORTC QOL-CIPN20). Results: Patients' probability estimates showed that the EORTC QLQ-CIPN20 sensory score was overall more highly related to the NCI-CTC sensory score. However, the vibration perception item of the TNSc had a higher probability to be scored 0 for EORTC QLQ-CIPN20 scores lower than 35, as vibration score 2 for EORTC QLQ-CIPN20 scores between 35 and 50 and as grade 3 or 4 for EORTC QLQ-CIPN20 scores higher than 50. The linear models showed a significant trend between each mISS item and increasing EORTC QLQ-CIPN20 sensory scores. Conclusion: None of the clinical items had a perfect relationship with patients' perception, and most of the discrepancies stood in the intermediate levels of CIPN severity. Our data indicate that to achieve a comprehensive knowledge of CIPN including a reliable assessment of both the severity and the quality of CIPN-related sensory impairment, clinical and PRO measures should be always combined.

Original language	English
Pages (from-to)	257-264
Journal	Annals of Oncology
Volume	25
Issue number	1
DOIs	https://doi.org/10.1093/annonc/mdt409
Publication status	Published - Jan 2014

Keywords

chemotherapy
neuropathy
assessment
patient-reported outcome measure
neurotoxicity

Access to Document

10.1093/annonc/mdt409

Cite this

Alberti, P., Rossi, E., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Frigeni, B., Bruna, J., Velasco, R., Argyriou, A. A., Kalofonos, H. P., Psimaras, D., Ricard, D., Pace, A., Galie, E., Briani, C., Dalla Torre, C., Faber, C. G., Lalisang, R. I., Boogerd, W., ... Cavaletti, G. (2014). Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Annals of Oncology, 25(1), 257-264. https://doi.org/10.1093/annonc/mdt409

@article{5ede130193944ed7a800ab02c344fdcd,

title = "Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin",

abstract = "Background: The different perception and assessment of chemotherapy-induced peripheral neurotoxicity (CIPN) between healthcare providers and patients has not yet been fully addressed, although these two approaches might eventually lead to inconsistent, possibly conflicting interpretation, especially regarding sensory impairment. Patients and methods: A cohort of 281 subjects with stable CIPN was evaluated with the National Cancer Institute-Common Toxicity Criteria (NCI-CTC v. 2.0) sensory scale, the clinical Total Neuropathy Score (TNSc (c)), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) sensory sumscore (mISS) and the European Organization for Research and Treatment of Cancer CIPN specific self-report questionnaire (EORTC QOL-CIPN20). Results: Patients' probability estimates showed that the EORTC QLQ-CIPN20 sensory score was overall more highly related to the NCI-CTC sensory score. However, the vibration perception item of the TNSc had a higher probability to be scored 0 for EORTC QLQ-CIPN20 scores lower than 35, as vibration score 2 for EORTC QLQ-CIPN20 scores between 35 and 50 and as grade 3 or 4 for EORTC QLQ-CIPN20 scores higher than 50. The linear models showed a significant trend between each mISS item and increasing EORTC QLQ-CIPN20 sensory scores. Conclusion: None of the clinical items had a perfect relationship with patients' perception, and most of the discrepancies stood in the intermediate levels of CIPN severity. Our data indicate that to achieve a comprehensive knowledge of CIPN including a reliable assessment of both the severity and the quality of CIPN-related sensory impairment, clinical and PRO measures should be always combined.",

keywords = "chemotherapy, neuropathy, assessment, patient-reported outcome measure, neurotoxicity",

author = "P. Alberti and E. Rossi and Cornblath, {D. R.} and Merkies, {I. S. J.} and Postma, {T. J.} and B. Frigeni and J. Bruna and R. Velasco and Argyriou, {A. A.} and Kalofonos, {H. P.} and D. Psimaras and D. Ricard and A. Pace and E. Galie and C. Briani and {Dalla Torre}, C. and Faber, {C. G.} and Lalisang, {R. I.} and W. Boogerd and D. Brandsma and S. Koeppen and J. Hense and D. Storey and S. Kerrigan and A. Schenone and S. Fabbri and Valsecchi, {M. G.} and G. Cavaletti",

year = "2014",

month = jan,

doi = "10.1093/annonc/mdt409",

language = "English",

volume = "25",

pages = "257--264",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "1",

}

Alberti, P, Rossi, E, Cornblath, DR, Merkies, ISJ, Postma, TJ, Frigeni, B, Bruna, J, Velasco, R, Argyriou, AA, Kalofonos, HP, Psimaras, D, Ricard, D, Pace, A, Galie, E, Briani, C, Dalla Torre, C, Faber, CG , Lalisang, RI, Boogerd, W, Brandsma, D, Koeppen, S, Hense, J, Storey, D, Kerrigan, S, Schenone, A, Fabbri, S, Valsecchi, MG & Cavaletti, G 2014, 'Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin', Annals of Oncology, vol. 25, no. 1, pp. 257-264. https://doi.org/10.1093/annonc/mdt409

TY - JOUR

T1 - Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin

AU - Alberti, P.

AU - Rossi, E.

AU - Cornblath, D. R.

AU - Merkies, I. S. J.

AU - Postma, T. J.

AU - Frigeni, B.

AU - Bruna, J.

AU - Velasco, R.

AU - Argyriou, A. A.

AU - Kalofonos, H. P.

AU - Psimaras, D.

AU - Ricard, D.

AU - Pace, A.

AU - Galie, E.

AU - Briani, C.

AU - Dalla Torre, C.

AU - Faber, C. G.

AU - Lalisang, R. I.

AU - Boogerd, W.

AU - Brandsma, D.

AU - Koeppen, S.

AU - Hense, J.

AU - Storey, D.

AU - Kerrigan, S.

AU - Schenone, A.

AU - Fabbri, S.

AU - Valsecchi, M. G.

AU - Cavaletti, G.

PY - 2014/1

Y1 - 2014/1

N2 - Background: The different perception and assessment of chemotherapy-induced peripheral neurotoxicity (CIPN) between healthcare providers and patients has not yet been fully addressed, although these two approaches might eventually lead to inconsistent, possibly conflicting interpretation, especially regarding sensory impairment. Patients and methods: A cohort of 281 subjects with stable CIPN was evaluated with the National Cancer Institute-Common Toxicity Criteria (NCI-CTC v. 2.0) sensory scale, the clinical Total Neuropathy Score (TNSc (c)), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) sensory sumscore (mISS) and the European Organization for Research and Treatment of Cancer CIPN specific self-report questionnaire (EORTC QOL-CIPN20). Results: Patients' probability estimates showed that the EORTC QLQ-CIPN20 sensory score was overall more highly related to the NCI-CTC sensory score. However, the vibration perception item of the TNSc had a higher probability to be scored 0 for EORTC QLQ-CIPN20 scores lower than 35, as vibration score 2 for EORTC QLQ-CIPN20 scores between 35 and 50 and as grade 3 or 4 for EORTC QLQ-CIPN20 scores higher than 50. The linear models showed a significant trend between each mISS item and increasing EORTC QLQ-CIPN20 sensory scores. Conclusion: None of the clinical items had a perfect relationship with patients' perception, and most of the discrepancies stood in the intermediate levels of CIPN severity. Our data indicate that to achieve a comprehensive knowledge of CIPN including a reliable assessment of both the severity and the quality of CIPN-related sensory impairment, clinical and PRO measures should be always combined.

AB - Background: The different perception and assessment of chemotherapy-induced peripheral neurotoxicity (CIPN) between healthcare providers and patients has not yet been fully addressed, although these two approaches might eventually lead to inconsistent, possibly conflicting interpretation, especially regarding sensory impairment. Patients and methods: A cohort of 281 subjects with stable CIPN was evaluated with the National Cancer Institute-Common Toxicity Criteria (NCI-CTC v. 2.0) sensory scale, the clinical Total Neuropathy Score (TNSc (c)), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) sensory sumscore (mISS) and the European Organization for Research and Treatment of Cancer CIPN specific self-report questionnaire (EORTC QOL-CIPN20). Results: Patients' probability estimates showed that the EORTC QLQ-CIPN20 sensory score was overall more highly related to the NCI-CTC sensory score. However, the vibration perception item of the TNSc had a higher probability to be scored 0 for EORTC QLQ-CIPN20 scores lower than 35, as vibration score 2 for EORTC QLQ-CIPN20 scores between 35 and 50 and as grade 3 or 4 for EORTC QLQ-CIPN20 scores higher than 50. The linear models showed a significant trend between each mISS item and increasing EORTC QLQ-CIPN20 sensory scores. Conclusion: None of the clinical items had a perfect relationship with patients' perception, and most of the discrepancies stood in the intermediate levels of CIPN severity. Our data indicate that to achieve a comprehensive knowledge of CIPN including a reliable assessment of both the severity and the quality of CIPN-related sensory impairment, clinical and PRO measures should be always combined.

KW - chemotherapy

KW - neuropathy

KW - assessment

KW - patient-reported outcome measure

KW - neurotoxicity

U2 - 10.1093/annonc/mdt409

DO - 10.1093/annonc/mdt409

M3 - Article

C2 - 24256846

VL - 25

SP - 257

EP - 264

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -